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Abstract
1. Background
Despite the advances made in the field of prevention and control of communicable diseases
over the last decade, the incidence and prevalence of Non-communicable diseases has increased
dramatically and in most countries after the illness Cardiovascular disease is the second most
common cause of death [1–5]. Lung Cancer (LC) is one of the most common cancers in the
international arena. This disease is the most important cause of mortality from cancer, so that
20% of the cancer deaths are specifically due to the LC. 17% of men and 9% of women, who are
diagnosed as the newly cases of cancer peer year, have LC [6].
Cigarette smoking is one of the most important risk factors for LC. Despite the descending
prevalence of cigarette smoking in the United States since the 1950s, LC is now known as one of
cancers with very high incidence, so that LC has the highest number of new cases after Prostate
cancer in men and after breast cancer in women [7,8]. In the United States, different studies have
shown a significant disparity in the incidence of LC in different races with an incidence of 50%
in African Americans men higher than white males [7,8]. In another study on the incidence of
disease in the United States, it was found that the incidence of LC was ascending in men until
1980 and in women up to 2007, but it was descending since then [8]. In the United States, LC
accounts for a significant proportion of mortality from cancer, so that about 27 out of 100 deaths
from cancer occurred due to LC [9].
The five-year survival rate for LC is very low, so that the 5-year survival rate of this cancer
was equal to 12.3% in 1970 and 16.3% in 2007. However, the survival rate of this disease is highly
associated with the diagnosis stage in such a way that the 5-year survival rate of this disease
was equal to 52% in patients, whose diseases were at the local stages, and 24% in patients with
diseases at the regional stage, while the 5-year survival rate for patients was equal to 4% in those
whose diseases were at distant stage. However, there are other factors that affect the survival rate
of disease, so that the survival rate is lower in males than females, in the elderly than adults, and
in the African American race than other races [10,11].
As the burden of this disease on public health is so much, and the changes in its risk factors
such as smoking is very different in the world, and due to the population growth and the
increasing proportion of older people in societies, it is essential to perform the continuous and
accurate epidemiology studies of this disease [12]. The incidence and mortality of LC are properly
Background: Lung Cancer (LC) is one of the most common cancers in the international arena.
The aim of this study was to investigate the geographical distribution of LC incidence and
mortality in the world in 2012, as well as the trend of incidence and mortality of LC during
1975 to 2010 based on the gender. Material and methods: In the present study, we extracted the
information on the incidence and mortality of LC in 184 countries from the International Agency
for Research on Cancer (IARC) (Project GLOBOCAN, 2012). The present study categorized and
presented the information on the Age-Standardized Incidence Rate (ASIR) and Age Standardized
Mortality Rate (ASMR) of LC based on the continents, world regions based on the development
level and Human Development Index (HDI). ASIR and ASMR of LC expressed per 100,000
people. Results: The highest ASIR and ASMR of LC occurred in North America (ASIR=38.3 and
ASMR=28.6), more developed regions (ASIR=30.8 and ASMR=24.2), and the WPRO region of
the WHO (ASIR=32.8 and ASMR=28.5), and those regions with very high HDI (ASIR=31 and
ASMR=23.9). Furthermore, the lowest ASIR and ASMR of LC occurred in Africa (ASIR=5 and
ASMR=4.5), the less developed regions (ASIR=20 and ASMR=18), the AFRO region (ASIR=3.9
and ASMR=3.5), and regions with low HDI (ASIR=5.4 and ASMR=4.8). Conclusion: The highest
ASIR and ASMR of LC occurred in North America, more developed regions, and the WPRO
region of the WHO, and those regions with very high HDI. Most regions of the world had
decreasing incidence and mortality of LC in men and increasing trend in women.
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and regularly monitored in developed countries [13–16] however, there are not enough numbers
of studies on the disparity in the distribution of incidence and mortality of this cancer based
on different geographical or Socio-Economic indexes for areas at the national and international
level [17]. Therefore, there are not identified geographical disparities caused by this disease at the
global level. The aim of this study was to investigate the geographical distribution of LC incidence
and mortality based on the development level, WHO classification, human development index
levels and the world’s continents in 2012, as well as the trend of incidence and mortality of LC
during 1975 to 2010 based on the gender in the worldwide.
2. Methods
In the present study, we extracted the information on the incidence and mortality of LC in 184
countries from the International Agency for Research on Cancer (IARC) (Project GLOBOCAN,
2012). GLOBOCAN is a database on various types of cancers and it is created by the World Health
Organization. It covers information on the number, raw rates, and age standardization of cancer
incidence, prevalence and mortality for different regions and countries. Currently, the available
data in GLOBOCAN is known as one of the newest international database on the cancer. Based
on the data of GLOBOCAN project, it is possible to investigate and compare the incidence and
mortality of cancer based on the type of cancer, age and gender groups for different regions of the
world.
The present study categorized and presented the information on the Age-Standardized
Incidence Rate (ASIR) and Age Standardized Mortality Rate (ASMR) of LC based on the
continents (Africa, Latin America and Caribbean, Northern America, Europe, Oceania, Asia),
world regions based on the development level (More developed regions and Less developed
regions) and human development index (very high, high, medium, or low).
We provided the information about the incidence and mortality of LC based on the number,
raw rates and the Age-Standardized rates in 2012. We also expressed raw and standardized rates
of incidence and mortality per 100,000 people. Geographical Distribution Map was prepared
for the ASIR and ASMR of this disease based on the age-specific rates. Detailed descriptions of
applied methods are presented in previous reports [18–21].
3. Results
(a) The ASIR and ASMR of LC in the world
In 2012, 1824701 new cases of LC were diagnosed worldwide. From this number, 1241601 (68.04%)
cases occurred in men and 583100 (31.96%) in women. In general, the ASIR of LC was equal to
23.1 (34.2 in men and 13.6 in women). The sex ratio (male to female) of the newly diagnosed LC
was equal to 2.13 (Figure 1).
There were also 1589925 deaths from LC during this year. From this number, 1098702 (69.1%)
cases occurred in men and 491223 (30.9%) in women. In general, the ASMR of LC was equal to
19.7 (30 were in men and 11.1 in women). The sex ratio of the mortality of LC was equal to 2.24
(Figure 2).
(b) The ASIR and ASMR of LC based on the continents
The ASIR of LC was equal to 38.3 (44 in men, and 33.8 in women) in North America, 29 (46.2 in
men, and 15.1 in women) in Europe, 25.3 (31.3 in men and 20 in women) in Oceania, 23.4 (35.2
in men and 12.7 in women) in Asia, 13.7 (18.7 in men and 9.6 in women) in Latin America, and 5
(7.7 in men and 2.6 in women) in Africa. From the total number of this disease in the world, the
highest proportion occurred in Asia and the lowest proportion in Oceania, so that 57.3% of cases
occurred in Asia, 22.5% in Europe, 13.2% in North America, 4.7% in Latin America, 1.6% in Africa
and 0.7% in Oceania (Table 1 and Figures 1, 2 and 3).
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Figure 1. Distribution of Age-Standardized Incidence Rate (ASIR) of Lung Cancer in the world based on the
results of the International Agency for Research on Cancer data (Globocan, 2012).
Figure 2. Distribution of Age-Standardized Mortality Rate (ASMR) of Lung Cancer in the world based on the
results of the International Agency for Research on Cancer data (Globocan, 2012).
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Table 1: The incidence rate of LC in different parts of the world in 2012
Population
Male Female All
Numbers Crude Rate ASR (W) Numbers Crude Rate ASR (W) Numbers Crude Rate ASR (W)
World 1241601 34.9 34.2 583100 16.7 13.6 1824701 25.9 23.1
More developed regions 490267 80.9 44.7 267947 41.9 19.6 758214 60.9 30.8
Less developed regions 751334 25.5 30.0 315153 11.0 11.1 1066487 18.4 20.0
Very High Human Development 440520 77.4 42.2 265905 45.6 21.8 706425 61.3 31.0
High Human Development 166118 32.4 32.1 54657 10.3 8.1 220775 21.2 18.7
Medium Human Development 607578 33.4 35.6 250192 14.4 13.1 857770 24.1 23.8
Low Human Development 26870 4.1 7.9 12039 1.9 3.1 38909 3.0 5.4
WHO Africa region (AFRO) 11786 2.7 5.5 6265 1.4 2.5 18051 2.1 3.9
WHO Americas region (PAHO) 177861 37.8 31.4 146440 30.3 21.6 324301 34.0 26.0
WHO East Mediterranean region (EMRO) 25592 8.0 12.6 6950 2.3 3.3 32542 5.2 7.9
WHO Europe region (EURO) 322752 73.8 46.9 125866 27.0 14.4 448618 49.7 28.7
WHO South-East Asia region (SEARO) 115658 12.2 15.7 46345 5.1 5.7 162003 8.7 10.5
WHO Western Pacific region (WPRO) 587774 62.2 48.9 251204 28.0 18.4 838978 45.5 32.8
IARC membership (24 countries) 514385 39.2 32.3 279144 21.5 14.6 793529 30.4 22.6
Middle-East and Northern Africa (MENA) 43562 19.1 27.1 9342 4.2 5.2 52904 11.8 15.6
Africa 21756 4.1 7.7 8558 1.6 2.6 30314 2.8 5.0
Sub-Saharan Africa 9891 2.3 4.8 5917 1.4 2.5 15808 1.8 3.6
Eastern Africa 3102 1.8 3.8 2049 1.2 2.2 5151 1.5 2.9
Middle Africa 584 0.9 2.0 288 0.4 0.8 872 0.7 1.4
Northern Africa 11865 11.4 15.6 2641 2.5 3.1 14506 7.0 9.0
Southern Africa 4821 16.6 26.1 2588 8.8 10.2 7409 12.6 16.9
Western Africa 1384 0.9 1.7 992 0.6 1.1 2376 0.7 1.4
Latin America and Caribbean 52325 17.6 18.7 32195 10.5 9.6 84520 14.0 13.7
Caribbean 5999 28.6 25.8 3542 16.7 13.5 9541 22.6 19.2
Central America 6874 8.7 10.2 3909 4.8 4.9 10783 6.7 7.4
Continued on next page
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South America 39452 19.9 20.8 24744 12.2 10.7 64196 16.0 15.2
Northern America 125536 72.4 44.0 114245 64.4 33.8 239781 68.4 38.3
Asia 742718 34.2 35.2 302977 14.6 12.7 1045695 24.6 23.4
Eastern Asia 556089 68.0 50.4 240446 31.2 19.2 796535 50.2 34.1
South-Eastern Asia 74031 24.5 29.6 30987 10.2 10.5 105018 17.3 19.2
South-Central Asia 80901 8.7 11.9 24843 2.8 3.4 105744 5.8 7.5
Western Asia 31697 25.5 37.6 6701 5.8 7.1 38398 16.0 21.7
Europe 290904 81.4 46.6 119316 31.1 15.1 410220 55.3 29.0
European Union (EU-28) 213663 86.0 45.1 98982 38.2 18.2 312645 61.6 30.5
Central and Eastern Europe 106961 77.6 53.5 31654 20.3 10.4 138615 47.2 27.8
Northern Europe 33458 67.8 34.6 26703 52.4 23.7 60161 60.0 28.6
Southern Europe 69933 90.3 46.4 21772 27.2 12.8 91705 58.2 28.2
Western Europe 80552 86.7 44.0 39187 40.5 20.0 119739 63.1 31.1
Oceania 8362 44.2 31.3 5809 30.8 20.0 14171 37.6 25.3
Australia/New Zealand 7811 57.3 32.7 5547 40.3 21.7 13358 48.8 26.8
Melanesia 331 7.1 14.3 163 3.6 5.8 494 5.4 9.7
Micronesia/Polynesia 220 35.2 42.7 99 16.3 17.5 319 25.9 29.7
Micronesia 108 39.1 47.5 58 21.3 22.9 166 30.3 34.8
Polynesia 112 32.1 39.3 41 12.2 13.5 153 22.4 25.9
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The ASMR of LC was equal to 28.6 (34.8 in men, and 23.5 in women) in North America, 24 (39.8
in men, and 11.8 in women) in Europe, 20.7 (31.6 in men and 11 in women) in Asia, 18.3 (23.1 in
men and 14.1 in women) in Oceania, 12 (16.7 in men and 8.1 in women) in Latin America, and 4.5
(7 in men and 2.4 in women) in Africa. From the total number of deaths of LC in the world, the
highest proportion occurred in Asia and the lowest proportion in Oceania, so that 58.8% of cases
occurred in Asia, 22.3% in Europe, 11.8% in North America, 4.7% in Latin America, 1.7% in Africa
and 0.7% in Oceania (Table 2 and Figure 3).
(c) The ASIR and ASMR of LC based on the development level
The ASIR of LC was equal to 30.8 (44.7 in men, and 19.6 in women) in more developed countries,
and 20 (30 in men, and 11.1 in women) in less developed regions. 58.4% of cases occurred in more
developed countries and 41.6% in less developed regions.
The mortality of LC was equal to 24.2 (36.8 in men, and 14.3 in women) in more developed regions,
and 18 (27.2 in men, and 9.8 in women) in less developed regions. 39.4% of cases occurred in more
developed regions and 60.6% in less developed regions.
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Table 2: The mortality rate of LC in different parts of the world in 2012
Population
Male Female All
Numbers Crude Rate ASR (W) Numbers Crude Rate ASR (W) Numbers Crude Rate ASR (W)
World 1098702 30.9 30.0 491223 14.0 11.1 1589925 22.5 19.7
More developed regions 416711 68.8 36.8 209859 32.8 14.3 626570 50.3 24.2
Less developed regions 681991 23.1 27.2 281364 9.8 9.8 963355 16.6 18.0
Very High Human Development 371192 65.2 34.1 206330 35.4 15.6 577522 50.1 23.9
High Human Development 148383 29.0 28.6 47284 8.9 6.9 195667 18.8 16.4
Medium Human Development 554792 30.5 32.6 226602 13.1 11.7 781394 22.0 21.6
Low Human Development 23881 3.7 7.1 10738 1.7 2.8 34619 2.7 4.8
WHO Africa region (AFRO) 10522 2.4 5.0 5586 1.3 2.3 16108 1.8 3.5
WHO Americas region (PAHO) 149462 31.7 25.9 112852 23.4 15.9 262314 27.5 20.4
WHO East Mediterranean region (EMRO) 22759 7.1 11.3 6218 2.0 2.9 28977 4.7 7.1
WHO Europe region (EURO) 283324 64.8 40.3 104879 22.5 11.3 388203 43.0 24.0
WHO South-East Asia region (SEARO) 104264 11.0 14.2 41952 4.6 5.2 146216 7.9 9.5
WHO Western Pacific region (WPRO) 528212 55.9 43.3 219708 24.5 15.4 747920 40.6 28.5
IARC membership (24 countries) 437684 33.3 27.0 219446 16.9 10.9 657130 25.1 18.2
Middle-East and Northern Africa (MENA) 38948 17.1 24.5 8225 3.7 4.6 47173 10.5 14.0
Africa 19430 3.6 7.0 7653 1.4 2.4 27083 2.5 4.5
Sub-Saharan Africa 8861 2.1 4.4 5282 1.2 2.2 14143 1.6 3.2
Eastern Africa 2809 1.6 3.5 1848 1.0 2.0 4657 1.3 2.7
Middle Africa 525 0.8 1.8 258 0.4 0.7 783 0.6 1.2
Northern Africa 10569 10.2 14.0 2371 2.3 2.8 12940 6.2 8.1
Southern Africa 4302 14.8 23.8 2316 7.8 9.1 6618 11.3 15.2
Western Africa 1225 0.8 1.5 860 0.5 1.0 2085 0.7 1.2
Latin America and Caribbean 47047 15.8 16.7 27555 9.0 8.1 74602 12.4 12.0
Caribbean 5607 26.8 23.7 3259 15.3 12.1 8866 21.0 17.5
Central America 6180 7.8 9.0 3482 4.3 4.3 9662 6.0 6.5
Continued on next page
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South America 35260 17.8 18.4 20814 10.3 8.9 56074 14.0 13.1
Northern America 102415 59.1 34.8 85297 48.1 23.5 187712 53.5 28.6
Asia 668765 30.8 31.6 267286 12.9 11.0 936051 22.0 20.7
Eastern Asia 501654 61.4 44.8 211141 27.4 16.2 712795 44.9 29.6
South-Eastern Asia 65763 21.8 26.6 27772 9.1 9.4 93535 15.4 17.2
South-Central Asia 72969 7.8 10.7 22519 2.5 3.1 95488 5.3 6.8
Western Asia 28379 22.8 34.0 5854 5.0 6.2 34233 14.2 19.4
Europe 254706 71.2 39.8 99142 25.8 11.8 353848 47.7 24.0
European Union (EU-28) 185589 74.7 37.7 82111 31.7 14.1 267700 52.7 24.7
Central and Eastern Europe 95692 69.5 47.6 26299 16.9 8.3 121991 41.5 24.1
Northern Europe 29606 60.0 29.7 22865 44.9 19.1 52471 52.3 23.8
Southern Europe 61345 79.2 39.1 18288 22.8 10.0 79633 50.6 23.2
Western Europe 68063 73.2 35.3 31690 32.7 14.8 99753 52.6 24.1
Oceania 6339 33.5 23.1 4290 22.8 14.1 10629 28.2 18.3
Australia/New Zealand 5838 42.9 23.5 4053 29.5 15.0 9891 36.1 18.9
Melanesia 303 6.5 13.3 139 3.1 5.0 442 4.8 8.8
Micronesia/Polynesia 198 31.7 38.4 98 16.2 17.3 296 24.0 27.4
Micronesia 93 33.7 41.7 52 19.1 20.8 145 26.5 30.8
Polynesia 105 30.1 36.0 46 13.7 14.8 151 22.1 24.9
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Figure 3. Regions and countries with highest Age-Standardized Incidence Rate (ASIR) and Age-Standardized
Mortality Rate (ASMR) of lung cancer in the world.
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(d) The ASIR and ASMR of LC according to the WHO classification
The ASIR of LC was equal to 32.8 (48.9 in men, and 18.4 in women) in WPRO, 28.7 (46.9 in men,
and 14.4 in women) in EURO, 26 (31.4 in men and 21.6 in women) in PAHO, 10.5 (15.7 in men and
5.7 in women) in SEARO, 7.9 (12.7 in men and 3.3 in women) in EMRO, and 3.9 (5.5 in men and
2.5 in women) in AFRO. From the total incidence of this disease, 46% occurred in WPRO, 24.6%
in EURO, 17.7% in PAHO, 8.9% in SEARO, 1.8% in EMRO, and 1% in AFRO (Table 1).
The ASMR of LC was equal to 28.5 (43.3 in men, and 15.4 in women) in WPRO, 24 (40.3 in men,
and 11.3 in women) in EURO, 20.4 (25.9 in men and 15.9 in women) in PAHO, 9.5 (14.2 in men
and 5.2 in women) in SEARO, 7.1 (11.3 in men and 2. in women) in EMRO, and 3.5 (5 in men and
2.3 in women) in AFRO. From the total mortality of this disease, 47.1% occurred in WPRO, 24.4%
in EURO, 16.5% in PAHO, 9.2% in SEARO, 1.8% in EMRO, and 1% in AFRO (Table 2).
Figure 4. Trends in Age-Standardized Incidence Rate (ASIR) of lung cancer in selected countries (per 100,000
men)
Figure 5. Trends in Age-Standardized Mortality Rate (ASMR) from lung cancer in selected countries (per 100,000
men)
(e) The ASIR and ASMR of LC according to the levels of Human
Development Index (HDI)
The ASIR of LC was equal to 31 (42.2 in men, and 21.8 in women) in regions with very high HDI,
18.7 (32.1 in men, and 8.1 in women) in regions with high HDI, 23.8 (35.6 in men and 13.1 in
women) in regions with medium HDI, and 5.4 (7.9 in men and 3.1 in women) in regions with low
HDI. From the total incidence of this disease, 47% occurred in regions with medium HDI, 38.7%
Mohammadian et al. Biomedical Research and Therapy 2018, 5(6):2348-2364
Biomed. Res. Ther. 2018, 5(6):2348-2364 2359
2360
B
iom
ed.
R
es.
Ther.
2018,5(6):
2349-2364
..............................................................
in regions with very high HDI, 12.1% in regions with high HDI, and 2.2% in regions with low
HDI (Table 1).
The ASMR of LC was equal to 23.9 (34.1 in men, and 15.6 in women) in regions with very high
HDI, 16.4 (28.6 in men, and 6.9 in women) in regions with high HDI, 21.6 (32.6 in men and 11.7
in women) in regions with medium HDI, and 4.8 (7.1 in men and 2.8 in women) in regions with
low HDI. From the total mortality of this disease, 49.1% occurred in regions with medium HDI,
36.4% in regions with very high HDI, 12.3% in regions with high HDI, and 2.2% in regions with
low HDI (Table 2).
Figure 6. Trends in Age Standardized Incidence Rate (ASIR) of lung cancer in selected countries (per 100,000
women).
Figure 7. Trends in Age Standardized Mortality Rate (ASMR) from lung cancer in selected countries (per 100,000
women).
(f) The trend of LC ASIR and ASMR during 1950 to 2010
The total trend of ASIR and ASMR of LC was descending in men during 1975 to 2010, while it
was quite different in women and it was ascending during this period. Figures 4, 5, 6 and 7show
the trend of incidence and mortality of LC in men and women in some countries during 1975 to
2010.
4. Discussion
The present study aimed to investigate the distribution of LC incidence and mortality worldwide
based on the WHO classification, the world’s continents, development level, and the HDI level
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based on the gender in 2012. It also studied the trend of incidence and mortality of LC based on the
gender for some selected countries during 1975 to 2010. In 2012, there were 1824701 new cases of
LC in worldwide, of which 68.04% were in men and 31.96% in women. This year also had 1589925
deaths from this disease of which 69.1% were in men and 30.9% in women. The highest ASIR and
ASMR of LC occurred in North America, more developed regions, and the WPRO region of the
WHO, and regions with very high HDI. Furthermore, the lowest ASIR and ASMR of LC occurred
in Africa, the less developed regions, the AFRO region, and regions with low HDI. The ASIR and
ASMR of LC was descending in men, but ascending in women in most of the world’s countries
from 1975 to 2010.
The highest ASIR and ASMR of LC occurred in areas with very high HDI, but the lowest rate
was seen in areas with low HDI. Similar results with the present research were found in a study
by Pakzad et al on the relationship between the HDI and the ASIR and ASMR of LC in Asian
countries. According to their study, an increase in the HDI led to the increased ASIR and ASMR
of LC, so that the correlation was equal to 0.345 between the HDI and the ASIR, and equal to 0.289
with ASMR, that it was statistically significant [17]. High life expectancy and average life span
were the main reasons for the high ASIR and ASMR of LC in regions with very high HDI. These
regions may also have much higher prevalence of smoking than other regions of the world. For
instance, the annual cigarette consumption per capita was increased more than 70 times (from 54
to 4,000 cigarettes) in the United States from 1880 to 1970 (12). On the other hand, there might be
the under estimate of incidence and mortality number of cancer cases in regions with low HDI due
to the existing problems with diagnosis of the disease as well as problems with the registration
of cancer cases, and thus the actual cases of this disease were higher than the diagnosed and
recorded cases. These problems have also been observed in other cancer studies [19,20,22–28].
In this study, the incidence and mortality number of LC in men was twice as high as in
women, so that 68% of incidence and 69% of mortality of LC occurred in men. Similar results
were observed in a study by Pakzad et al in Asian countries, to that 71.13% of new cases and
71.45% of deaths occurred in men in Asia during 2012 [17]. Probably, the main reason for the
disparity in the incidence and mortality of LC among men and women is the disparity in their
exposure to the risk factors of the disease.
The geographical distribution of LC was largely associated with the prevalence of cigarette
smoking, so that in Kentucky State of the United States, where the prevalence of cigarette smoking
was equal to 30%, the ASIR of LC was 125.9 in men, and 80.3 in women per 100,000 people, while
in California, where the prevalence of cigarette smoking was 14%, the ASIR of LC was 60.4 in
men and 44.4% in women per 100,000 people [29]. During 1973 to 2007, the incidence of LC was
steadily decreasing in white women in California, while no decreasing trend of mortality was seen
in women in Midwestern and Southern States, indicating the effectiveness of control programs in
reducing the incidence of cigarette smoking in California State [30].
The maximum prevalence of cigarette smoking in men has been two decades earlier than
women; hence, it is expected that the epidemic of this LC will begin in women at a time interval
after men. The incidence of LC in men has been descending over the past few decades, while the
incidence of this disease is still ascending in women [30]. Despite the fact that the number of men,
who annually die from LC, is much higher than women, it is expected that over the years to come
the disparity in mortality rates between both genders will become minimal [10].
Cigarette is thus one of the most important factors affecting the incidence of LC worldwide.
Furthermore, due to the high cost and limited effectiveness of screening methods and therapeutic
measures in LC, cigarette is one of the key factors in the death from LC [31]. Therefore, effective
measures can be taken to reduce the incidence of cigarette smoking to reduce the burden of
LC in the global arena especially in the African regions and some Asian countries with limited
access to screening and treatment programs [32]. In areas such as Australia, California and Hong
Kong, which have begun the cigarette prevention programs, the incidence of LC is expected to
reduce significantly especially in men. Since there is a long latency interval between smoking and
occurrence of LC, the incidence of LC will significantly increase in countries like China, where
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there is not any adequate program to reduce the prevalence of cigarette smoking, in the upcoming
decades [33].
Therefore, governments should adopt appropriate planning and policies to prevent LC. In
addition to reduction of the prevalence of smoking, they should also reduce the exposure to other
well-known risk factors such as Asbestos, Radon, air pollution, occupational carcinogens and
second-hand smoke [34,35].
Study Limitations
This study, has been conducted using data of GLOBOCAN project of World Health
Organization(WHO) in 2012. The aim of the GLOBOCAN project is to provide contemporary
estimates of the incidence, mortality and prevalence from major types of cancer, at national level,
for 184 countries of the world. Although data from the GLOBOCAN project is currently the most
comprehensive source of information on the distribution of cancers worldwide. Nevertheless,
one of the limitations of this study is the use of data of 2012, due to the lack of newer data in the
global level. Also, the quality of collected cancer data in the GLOBOCAN project is not similar in
all countries especially those with medium or low HDI, so that the estimates of some countries
are based on the recorded cases of cancer in limited areas or based on estimates from neighboring
countries [36].
5. Conclusions
The highest ASIR and ASMR of LC occurred in North America, more developed regions, and the
WPRO region of the WHO, and those regions with very high HDI. Furthermore, the lowest ASIR
and ASMR of LC occurred in Africa, the less developed regions, the AFRO region, and regions
with low human development indexes. Most regions of the world had decreasing incidence and
mortality of LC in men and increasing trend in women.
6. Open Access
This article is distributed under the terms of the Creative Commons Attribution License (CC-BY
4.0) which permits any use, distribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
7. List of abbreviations
AFRO: WHO Africa region, ASIR: Age- Standardized Incidence Rate, ASMR: Age- Standardized
Mortality Rate, EMRO: WHO East Mediterranean region, EURO: WHO Europe region, HDI:
Human Development Index, IARC: International Agency for Research on Cancer, PAHO: WHO
Americas region, SEARO: WHO South-East Asia region, WHO: World Health Organization,
WPRO: WHO Western Pacific region
8. Ethics approval and consent to participate
Not to be applied
9. Competing interests
The authors declare that they have no conflicts of interest.
10. Funding
None
Mohammadian et al. Biomedical Research and Therapy 2018, 5(6):2348-2364
Biomed. Res. Ther. 2018, 5(6):2348-2364 2362
2363
B
iom
ed.
R
es.
Ther.
2018,5(6):
2349-2364
..............................................................
11. Authors’ contributions
All authors contributed to the design of the research. MM, HS, MA, FAB and AMH extracted the
data and summarized it. All authors drafted the first version. HSG, AS, AMH and KAB edited
the first draft. All authors reviewed, commented and approved the final draft.
References
1. Hafshejani ABM, Baradaran H, Sarrafzadegan N, Lari MA, Ramezani A, Hosseini SH,
Hafshejani FA. 2012a Predicting factors of short-term survival in patients with acute
myocardial infarction in Isfahan using a cox regression model. Iranian Journal of Epidemiology
8, 39–47.
2. Hafshejani AM, Sarrafzadegan N, Moghaddam A, Baradaran HR, Hosseini S, Lari MA. 2012b
Gender Difference in Determinants of Short-Term Survival of Patients with Acute Myocardial
Infarction in Isfahan, Iran.. Journal of Isfahan Medical School 30.
3. Mohammadian-Hafshejani A, Sarrafzadegan N, Hosseini S, Baradaran HR, Roohafza H,
Sadeghi M, Asadi-Lari M. 2014 Seasonal pattern in admissions and mortality from acute
myocardial infarction in elderly patients in Isfahan, Iran. ARYA atherosclerosis 10, 46.
4. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, Charlson F, Davis A,
Degenhardt L, Dicker D et al.. 2015 Global, regional, and national incidence, prevalence, and
years lived with disability for 301 acute and chronic diseases and injuries in 188 countries,
1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet 386,
743–800.
5. Hu F, Hu B, Chen R, Ma Y, Niu L, Qin X, Hu Z. 2014 A systematic review of social capital and
chronic non-communicable diseases. Bioscience trends 8, 290–296.
6. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 2015 Global cancer statistics,
2012. CA: a cancer journal for clinicians 65, 87–108.
7. Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, Bray F. 2014
International trends in lung cancer incidence by histological subtype: adenocarcinoma
stabilizing in men but still increasing in women. Lung cancer 84, 13–22.
8. Meza R, Meernik C, Jeon J, Cote ML. 2015 Lung cancer incidence trends by gender, race and
histology in the United States, 1973-2010. PloS one 10, e0121323.
9. Siegel R, Naishadham D, Jemal A. 2013 Cancer statistics, 2013. CA: a cancer journal for clinicians
63, 11–30.
10. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. 2013 Epidemiology of lung cancer:
Diagnosis and management of lung cancer: American College of Chest Physicians evidence-
based clinical practice guidelines. Chest 143, e1S–e29S.
11. Ries LA, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg LX, Eisner MP, Horner
MJ, Howlader N et al.. 2006 SEER cancer statistics review, 1975-2003. .
12. Cheng TYD, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. 2016 The international
epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. Journal of
Thoracic Oncology 11, 1653–1671.
13. Bosetti C, Malvezzi M, Rosso T, Bertuccio P, Gallus S, Chatenoud L, Levi F, Negri E, Vecchia
CL. 2012 Lung cancer mortality in European women: trends and predictions. Lung Cancer 78,
171–178.
14. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman
D, Bray F. 2013 Cancer incidence and mortality patterns in Europe: estimates for 40 countries
in 2012. European journal of cancer 49, 1374–1403.
15. Blajer JAGW, Mariusz K. 2002 The Inverse Simulation Study of Aircraft Flight Path
Reconstruction. Transport XVII, 103–107.
16. Lewis DR, Check DP, Caporaso NE, Travis WD, Devesa SS. 2014 US lung cancer trends by
histologic type. Cancer 120, 2883–2892.
17. Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, Pakzad I, Salehiniya H. 2015 The
incidence and mortality of lung cancer and their relationship to development in Asia.
Translational lung cancer research 4, 763.
18. Arabsalmani M, Mohammadian-Hafshejani A, Ghoncheh M, Hadadian F, Towhidi F, Vafaee
K, Salehiniya H. 2017 Incidence and mortality of kidney cancers, and human development
index in Asia; a matter of concern. Journal of nephropathology 6, 30.
Mohammadian et al. Biomedical Research and Therapy 2018, 5(6):2348-2364
Biomed. Res. Ther. 2018, 5(6):2348-2364 2363
2364
B
iom
ed.
R
es.
Ther.
2018,5(6):
2349-2364
..............................................................
19. Arabsalmani M, Mirzaei M, Soroush A, Towhidi F, Salehiniya H. 2016 Incidence and mortality
of liver cancer and their relationship with the human development index in the world.
Biomedical Research and Therapy 3, 800–807.
20. Rafiemanesh H, Mohammadian-Hafshejani A, Ghoncheh M, Sepehri Z, Shamlou R,
Salehiniya H, Towhidi F, Makhsosi BR. 2016 Incidence and mortality of colorectal cancer and
relationships with the human development index across the world. Asian Pacific journal of
cancer prevention: APJCP 17, 2465–73.
21. Shuja M, Farsani SI, Salehiniya H, Khazaei S, Mohammadian M, Aryaie M, Bagheri P, Bakeshei
FA, Mohammadian-Hafshejani A. 2017 Assessment the association between liver cancer
incidence and mortality rate with human development index in the European countries in
2012. Biomedical Research and Therapy 4, 1185–1197.
22. Pakzad R, Mohammadian-Hafshejani A, Khosravi B, Soltani S, Pakzad I, Mohammadian M,
Salehiniya H, Momenimovahed Z. 2016 The incidence and mortality of esophageal cancer and
their relationship to development in Asia. Annals of translational medicine 4.
23. Razi S, Ghoncheh M, Mohammadian-Hafshejani A, Aziznejhad H, Mohammadian M,
Salehiniya H. 2016 The incidence and mortality of ovarian cancer and their relationship with
the Human Development Index in Asia. ecancermedicalscience 10.
24. Rafiemanesh H, Mehtarpoor M, Mohammadian-Hafshejani A, Salehiniya H, Enayatrad M,
Khazaei S. 2015 Cancer epidemiology and trends in Sistan and Baluchestan province, Iran.
Medical journal of the Islamic Republic of Iran 29, 254.
25. Razi S, Enayatrad M, Mohammadian-Hafshejani A, Salehiniya H et al.. 2015 The
epidemiology of skin cancer and its trend in Iran. International journal of preventive medicine
6.
26. Hassanipour-Azgomi S, Mohammadian-Hafshejani A, Ghoncheh M, Towhidi F,
Jamehshorani S, Salehiniya H. 2016 Incidence and mortality of prostate cancer and their
relationship with the Human Development Index worldwide. Prostate international 4, 118–124.
27. Rafiemanesh H, Maleki F, Mohammadian-Hafshejani A, Salemi M, Salehiniya H. 2016 The
trend in histological changes and the incidence of esophagus cancer in Iran (2003-2008).
International journal of preventive medicine 7.
28. Salehiniya H, Dashdebi SG, Rafiemanesh H, Mohammadian-Hafshejani A, Enayatrad M. 2016
Time Trend Analysis of Cancer Incidence in Caspian Sea, 2004-2009: A Population-based
Cancer Registries Study (northern Iran). Caspian journal of internal medicine 7, 25.
29. Siegel R, Ma J, Zou Z, Jemal A. 2014 Cancer statistics, 2014. CA: a cancer journal for clinicians
64, 9–29.
30. Jemal A, Ma J, Rosenberg PS, Siegel R, Anderson WF. 2012 Increasing lung cancer death rates
among young women in southern and midwestern States. Journal of Clinical Oncology 30, 2739.
31. Ezzati M, Henley SJ, Lopez AD, Thun MJ. 2005 Role of smoking in global and regional cancer
epidemiology: current patterns and data needs. International journal of cancer 116, 963–971.
32. Winkler V, Ott JJ, Cowan M, Becher H. 2013 Smoking prevalence and its impacts on lung
cancer mortality in Sub-Saharan Africa: an epidemiological study. Preventive medicine 57, 634–
640.
33. Paskett ED, Bernardo BM, Khuri FR. 2015 Tobacco and China: the worst is yet to come. Cancer
121, 3052–3054.
34. Laughlin JM. 2012 An historical overview of radon and its progeny: applications and health
effects. Radiation protection dosimetry 152, 2–8.
35. Wong CM, Vichit-Vadakan N, Vajanapoom N, Ostro B, Thach TQ, Chau PY, Chan EK, Chung
RY, Ou CQ, Yang L et al.. 2010 Part 5. Public health and air pollution in Asia (PAPA): a
combined analysis of four studies of air pollution and mortality.. Research report (Health Effects
Institute) pp. 377–418.
36. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D,
Bray F. 2015 Cancer incidence and mortality worldwide: sources, methods and major patterns
in GLOBOCAN 2012. International journal of cancer 136.
Mohammadian et al. Biomedical Research and Therapy 2018, 5(6):2348-2364
Biomed. Res. Ther. 2018, 5(6):2348-2364 2364
